GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Cash Ratio

SpectraScience (SpectraScience) Cash Ratio : 0.00 (As of Sep. 2017)


View and export this data going back to . Start your Free Trial

What is SpectraScience Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. SpectraScience's Cash Ratio for the quarter that ended in Sep. 2017 was 0.00.

SpectraScience has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for SpectraScience's Cash Ratio or its related term are showing as below:

SCIE's Cash Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.2
* Ranked among companies with meaningful Cash Ratio only.

SpectraScience Cash Ratio Historical Data

The historical data trend for SpectraScience's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Cash Ratio Chart

SpectraScience Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.05 0.03 0.01 -

SpectraScience Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 - -

Competitive Comparison of SpectraScience's Cash Ratio

For the Medical Devices subindustry, SpectraScience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraScience's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's Cash Ratio distribution charts can be found below:

* The bar in red indicates where SpectraScience's Cash Ratio falls into.



SpectraScience Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

SpectraScience's Cash Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Cash Ratio (A: Dec. 2016 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.004/10.802
=0.00

SpectraScience's Cash Ratio for the quarter that ended in Sep. 2017 is calculated as:

Cash Ratio (Q: Sep. 2017 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.028/12.805
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraScience  (GREY:SCIE) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


SpectraScience Cash Ratio Related Terms

Thank you for viewing the detailed overview of SpectraScience's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines